HANSAH PHARMA (03692) Signs Licensing Agreement with Roche

Hansoh Pharma (03692) announced on October 16, 2025 (after trading hours) that its wholly-owned subsidiaries Shanghai Hansohn Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. (referred to as the "licensor") have entered into a licensing agreement with F. Hoffmann-La Roche Ltd (the "licensee"). According to the licensing agreement, the licensor will grant the licensee a global exclusive license (excluding Mainland China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize HS-20110 (the product). The licensor will receive an upfront payment of $80 million and will be eligible to receive up to $1.45 billion in milestone payments based on the development, regulatory approval, and commercialization progress of the product, as well as tiered royalties on future potential product sales. The product is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in China and the United States. The licensee is a subsidiary of Roche Holding AG, listed on the Swiss Stock Exchange. Roche, founded in Basel, Switzerland in 1896, is one of the oldest brand-name pharmaceutical manufacturers and has evolved into a global leader in biotechnology and in vitro diagnostics. The board believes that entering into this licensing agreement is in the overall best interests of the company and its shareholders. The company will also maximize the scientific and commercial value of its technology platform through this opportunity.